Literature DB >> 16394084

The effects of gonadotropin suppression and selective replacement on insulin-like factor 3 secretion in normal adult men.

Katrine Bay1, Kati L Matthiesson, Robert I McLachlan, Anna-Maria Andersson.   

Abstract

CONTEXT: Gonadotropic regulation of the testicular Leydig cell hormone insulin-like factor 3 (INSL3) is incompletely characterized.
OBJECTIVE: The objective of this study was to assess the effects of gonadotropin suppression and induced or spontaneous recovery on serum INSL3. DESIGN AND PARTICIPANTS: Serum samples from 15 men enrolled in a short-term study of gonadotropin stimulation, suppression, and recovery and 11 men in a long-term study of gonadotropin suppression and spontaneous recovery were analyzed for INSL3. INTERVENTION: Gonadotropins were suppressed by exogenous testosterone and progestin. Recovery was spontaneous or induced with exogenous gonadotropins. OUTCOME MEASURE: The outcome measure was serum INSL3 in relation to other reproductive hormones.
RESULTS: Serum INSL3 was not acutely sensitive to gonadotropins. In both studies, INSL3 declined markedly with gonadotropin suppression (6-13.5% of baseline; P < 0.05). In the short-term study, human chorionic gonadotropin partially restored suppressed serum INSL3 within 4 d of administration (from 7.5 to 38.3% baseline; P < 0.05); the increase correlated with the corresponding increase in serum pro-alphaC (r = 0.82; P < 0.01). FSH did not stimulate the suppressed INSL3. In the long-term study, serum testosterone recovered significantly better (80% baseline) compared with serum INSL3 (38.9% baseline; P < 0.01) in the presence of fully recovered serum LH.
CONCLUSIONS: INSL3 is not sensitive to gonadotropin stimulation in normal men, but declines markedly in response to gonadotropin deprivation. After suppression, INSL3 was responsive to hCG 4 d after administration. After long-term suppression, INSL3 did not recover to the same degree as testosterone, suggesting that INSL3 is more sensitive to Leydig cell impairment than testosterone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394084     DOI: 10.1210/jc.2005-1865

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Serum insulin-like factor 3 quantification by LC-MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome.

Authors:  Trine Holm Johannsen; Marie Lindhardt Ljubicic; Jacques Young; Séverine Trabado; Jørgen Holm Petersen; Allan Linneberg; Jakob Albrethsen; Anders Juul
Journal:  Endocrine       Date:  2021-01-22       Impact factor: 3.633

Review 2.  Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.

Authors:  Alberto Ferlin; Luca De Toni; Marco Sandri; Carlo Foresta
Journal:  Br J Pharmacol       Date:  2016-05-05       Impact factor: 8.739

3.  Insulin-like factor 3 plasma levels in acromegaly before and after somatostatin analog treatment.

Authors:  Marco Rossato; Francesca Dassie; Valentina Silvestrin; Chiara Martini; Roberto Vettor; Pietro Maffei
Journal:  Endocrine       Date:  2014-06-12       Impact factor: 3.633

Review 4.  The gonadal function in obese adolescents: review.

Authors:  Rosita A Condorelli; Aldo E Calogero; Enzo Vicari; Laura Mongioi'; Vincenzo Favilla; Giuseppe Morgia; Sebastiano Cimino; Giorgio Russo; Sandro La Vignera
Journal:  J Endocrinol Invest       Date:  2014-06-13       Impact factor: 4.256

Review 5.  Testicular function and bone metabolism--beyond testosterone.

Authors:  Alberto Ferlin; Riccardo Selice; Umberto Carraro; Carlo Foresta
Journal:  Nat Rev Endocrinol       Date:  2013-07-16       Impact factor: 43.330

6.  Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.

Authors:  A Gambineri; L Patton; O Prontera; F Fanelli; W Ciampaglia; G E Cognigni; U Pagotto; R Pasquali
Journal:  J Endocrinol Invest       Date:  2011-05-17       Impact factor: 4.256

7.  Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial.

Authors:  Mara Y Roth; Kat Lin; Katrine Bay; John K Amory; Bradley D Anawalt; Alvin M Matsumoto; Brett T Marck; William J Bremner; Stephanie T Page
Journal:  Fertil Steril       Date:  2012-10-03       Impact factor: 7.329

8.  Increased proliferation but decreased steroidogenic capacity in Leydig cells from mice lacking cyclin-dependent kinase inhibitor 1B.

Authors:  Han Lin; Guo-Xin Hu; Lei Dong; Qiang Dong; Motoko Mukai; Bing-Bing Chen; Denise R Holsberger; Chantal M Sottas; Paul S Cooke; Qing-Quan Lian; Xiao-Kun Li; Ren-Shan Ge
Journal:  Biol Reprod       Date:  2009-02-11       Impact factor: 4.285

9.  Mutations in the insulin-like factor 3 receptor are associated with osteoporosis.

Authors:  Alberto Ferlin; Anastasia Pepe; Lisa Gianesello; Andrea Garolla; Shu Feng; Sandro Giannini; Manuela Zaccolo; Arianna Facciolli; Roy Morello; Alexander I Agoulnik; Carlo Foresta
Journal:  J Bone Miner Res       Date:  2008-05       Impact factor: 6.741

Review 10.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.